Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drug
Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public offering ...
April 24, 2026 11:03 AM EDTUpdated 11 hours ago News Briefing Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drug ENDPOINTS Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that